PUBLISHER: IMARC | PRODUCT CODE: 1468069
PUBLISHER: IMARC | PRODUCT CODE: 1468069
The global bioabsorbable stents market size reached US$ 409.4 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 764.2 Million by 2032, exhibiting a growth rate (CAGR) of 7% during 2024-2032.
Bioabsorbable stents (BRS) are coated with an antiproliferative drug or gene that dissolves over time to restore vessel patency and permit remodeling while retaining recoil. It helps in regulating blood flow at branch points and limiting the amount of blood to areas of the vascular network while maintaining the flow at low perfusion. It also improves lesion imaging with cardiac computed tomography (CT) and magnetic resonance imaging (MRI). In addition, it leaves no residual scaffold, reduces vessel irritation and inflammation, and facilitates repeat treatments to the same site. As a result, BRS finds extensive applications in hospitals and cardiac centers across the globe.
The growing prevalence of cardiovascular diseases due to an unhealthy diet, physical inactivity, and excessive consumption of tobacco and alcohol represents one of the factors driving the market. Moreover, there is a rise in the utilization of percutaneous coronary intervention (PCI) procedures to open a blocked artery for carrying oxygen-rich blood through the body. This, along with the expanding healthcare industry, is contributing to the growth of the market. Besides this, the increasing awareness among the masses about the benefits of bioabsorbable stents is offering lucrative growth opportunities to industry investors. In addition, the growing demand for minimally invasive procedures due to less postoperative pain, fewer operative and postoperative complications, shortened hospital stay, and faster recovery times is positively influencing the market. Apart from this, key market players are extensively investing in research and development (R&D) activities to introduce SLENDER integrated delivery system (IDS) fixed-wire and DIRECT RX bioabsorbable rapid-exchange drug-eluting stent (DES) systems to treat coronary artery disease. They are also focusing on developing polymer-based stents, which is expected to bolster the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global bioabsorbable stents market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on biomaterial, absorption rate, application and end user.
Polymer-based Bioabsorbable Stents
Metal-based Bioabsorbable Stents
Slow-Absorption Stents
Fast-Absorption Stents
Coronary Artery Disease
Peripheral Artery Disease
Hospitals
Cardiac Centers
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arterius Limited, B. Braun SE, Biotronik SE & Co. KG, Boston Scientific Corporation, Elixir Medical Corporation, Kyoto Medical Planning Co. Ltd., Lepu Medical Technology (Beijing) Co. Ltd., Meril Life Sciences Pvt. Ltd., Reva Medical LLC and Terumo Corporation.